[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371406-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371406-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tuxedo-4-phase-ii-study-of-trastuzumab-deruxtecan-in-her2-low-breast-cancer-with-new-or-progressing-brain-metastases","TUXEDO-4 - phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases","","Breast cancer (BC) is a leading cause of leptomeningeal disease (LMD) and a major contributor to brain metastases (BMs), both linked to substantial morbidity and mortality with constrained treatment options. Trastuzumab deruxtecan (T-DXd), an antibody drug conjugate targeting HER2 and delivering a topoisomerase I inhibitor, has demonstrated activity in HER2-positive and HER2-low tumors, including CNS involvement. Evidence in HER2-low BC with BMs and/or LMD remains limited. TUXEDO-4 is a two-stage, single-arm phase II trial designed to recruit 27 adults and evaluate T-DXd efficacy in this setting.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tuxedo-4-phase-ii-study-of-trastuzumab-deruxtecan-in-her2-low-breast-cancer-with-new-or-progressing-brain-metastases/371406/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tuxedo-4-phase-ii-study-of-trastuzumab-deruxtecan-in-her2-low-breast-cancer-with-new-or-progressing-brain-metastases/371406.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What medical problem does the TUXEDO-4 phase II trial target?","Question",{"text":63,"@type":64},"The trial targets HER2-low metastatic breast cancer presenting with newly diagnosed or progressing brain metastases, with or without type II leptomeningeal disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is TUXEDO-4 designed and how many patients will it enroll?",{"text":68,"@type":64},"TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design phase II trial. It will recruit 27 adult patients.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is T-DXd being studied in HER2-low breast cancer with CNS involvement?",{"text":72,"@type":64},"T-DXd has shown clinical activity in HER2-positive and HER2-low breast cancer in prior settings, including CNS involvement in HER2-positive patients. However, activity data in HER2-low patients with brain metastases and/or leptomeningeal disease are limited.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371406,1790419316,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","FUTURE ONCOLOGY  \n2025, VOL. 21, NO. 9, 1065–1073  \n[https://doi.org/10.1080/14796694.2025.2470604](https://doi.org/10.1080/14796694.2025.2470604)  \nCLINICAL TRIAL PROTOCOL  \nTUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases  \nMaximilian Marholda, Marta Vaz Batistab,c, Isabel Blancasd,e,f, Cristina Moralesg, Cristina Saura-Manichh,  \nCristina Saavedrai,j, Manuel Ruíz-Borregok, Patricia Cortezj, Felipe Slebec, Marta Campolierc, Juliana Carvalho Santosc, José Antonio Guerrero-Martínezc, Carlos Jiménez-Corteganac, Beate Rottenmannera, Heidrun Forstnera,  \nRupert Bartscha and Matthias Preussera  \naDepartment of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria; bDepartment of Oncology, Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal; cMedica Scientia Innovation Research (MEDSIR), Barcelona, Spain; dDepartment of Oncology, Hospital Universitario Clínico San Cecilio, Granada, Spain; eMedicine Department, University of Granada, Granada, Spain; fÁrea de Oncología Instituto de Investigación Biosanitaria de Granada, Granada, Spain; gServicio de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain; hVall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain; iDepartamento de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain; jIOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain; kServicio de Oncología Médica, Hospital Virgen del Rocío, Sevilla, Spain  \nABSTRACT  \nBreast cancer (BC) is the most common cause of leptomeningeal disease (LMD) and the second most common cause of brain metastases (BMs) among all solid malignancies. Both BMs and LMD are associated with high morbidity and mortality and treatment options are limited. Trastuzumab deruxtecan (T-DXd), an antibody drug conjugate combining a HER2-targeting antibody with a topoisomerase I inhibitor, has shown activity in HER2-positive (HER2[+]) and HER2-low tumors in both preclinical and clinical settings. Similarly, T-DXd has shown efficacy in HER2[+] BC patients with central nervous system (CNS) involvement. However, data on activity in HER2-low BC patients with BMs and/or LMD using T-DXd are limited. TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design, phase II trial (NCT06048718) that will recruit a total of 27 adult patients (13 in the first stage, and 14 in second stage depending on responses in the first stage) to evaluate T-DXd in the HER2-low metastatic BC population presenting with newly diagnosed or progressing BM with or without type II LMD.  \nClinical trial registration: NCT06048718 ([clinicaltrials.gov](clinicaltrials.gov)); 2023-506,702-39–00 (EudraCT number).  \nPLAIN LANGUAGE SUMMARY  \nBreast cancer cells often spread to the brain (brain metastases) or the membranes surrounding the brain and spinal cord (leptomeningeal disease) . Therapies to treat these serious conditions are limited. Trastuzumab deruxtecan (T-DXd), which targets a protein called HER2 (found on the surface of breast cells to control their growth) and includes a powerful anti-cancer component to kill the tumor cells, has shown clinically meaningful results in both HER2-positive (high concentration of HER2 proteins) and HER2-low (low concentration of HER2 proteins) breast cancers. Interestingly, T-DXd has successfully worked in HER2-positive breast cancer patients with brain metastases and/or leptomeningeal disease, but results in their HER2-low counterparts are limited. TUXEDO-4 is a medical study to evaluate the effectiveness of T-DXd in HER2-low breast cancer patients with recently diagnosed or worsening brain metastases, with or without aggressive leptomeningeal disease. The study is taking place in Austria and Spain, and will recruit 27 adult patients. TUXEDO-4 trial TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design, phas","cbCaibZUeAdvPufI","https://ap.wps.com/l/cbCaibZUeAdvPufI","pdf",1223450,"English","# Abstract\n# Plain language summary\n# TUXEDO-4 trial\n## Article history\n## Keywords\n## Contact","[{\"question\":\"What medical problem does the TUXEDO-4 phase II trial target?\",\"answer\":\"The trial targets HER2-low metastatic breast cancer presenting with newly diagnosed or progressing brain metastases, with or without type II leptomeningeal disease.\"},{\"question\":\"How is TUXEDO-4 designed and how many patients will it enroll?\",\"answer\":\"TUXEDO-4 is an international, multicenter, single-arm, two-stage optimal Simon’s design phase II trial. It will recruit 27 adult patients.\"},{\"question\":\"Why is T-DXd being studied in HER2-low breast cancer with CNS involvement?\",\"answer\":\"T-DXd has shown clinical activity in HER2-positive and HER2-low breast cancer in prior settings, including CNS involvement in HER2-positive patients. However, activity data in HER2-low patients with brain metastases and/or leptomeningeal disease are limited.\"}]","TUXEDO-4 - phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases | PDF",1790191995,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa2b84a1e212a28b7d491876a18f3065.webp",983,1280,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea3fa8eb058ae1c46f4be6f8df26592f.webp",982,1278,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29e90b5f2db8c30544a2cb3e9650d645.webp",981,1277,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e4a36e071e2d90cf549ed98e0a2c3dc.webp",980,1276]